Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
This study has been terminated.
Study NCT00062699   Information provided by Abbott
First Received: June 11, 2003   Last Updated: July 31, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
End-Stage Kidney Disease
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
More general conditions related to this trial
Kidney Failure
Renal Insufficiency
Urologic Diseases
Interventions listed in this trial
Zemplar (paricalcitol injection)
Calcijex
Additional drug interventions recognized in this trial
Calcitriol
More general drug interventions related to this trial
Bone Density Conservation Agents
Calcium Channel Agonists
Cardiovascular Agents
Growth Substances
Membrane Transport Modulators
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasoconstrictor Agents
Vitamins
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services